CIK 0001357874
- Non-accelerated filer
- Smaller reporting company
PRECISION BIOSCIENCES INC
Sign in to watch- Ticker
- DTIL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- May 21
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 919-314-5512
- Business address
- 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
- Open-market buys, last 90 days
- $29,501
- in 3 filings
- Open-market sales, last 90 days
- $27,505
- in 1 filing, $28K under 10b5-1 plans
Net +$1,996. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-29 | JANTZ DEREK Chief Scientific Officer | Sale | −6,444 | $12.25 | $79K | 3,907,345 |
| 2021-01-29 | JANTZ DEREK Chief Scientific Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −21,515 | 258,168 | ||
| 2021-01-28 | JANTZ DEREK Chief Scientific Officer | Exercise or conversion | +21,514 | $0.04 | $861 | 3,898,718 |
| 2021-01-28 | JANTZ DEREK Chief Scientific Officer | Sale | −6,444 | $11.97 | $77K | 3,892,274 |
| 2021-01-28 | JANTZ DEREK Chief Scientific Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −21,514 | 279,683 | ||
| 2021-01-27 | JANTZ DEREK Chief Scientific Officer | Exercise or conversion | +21,514 | $0.04 | $861 | 3,884,252 |
| 2021-01-27 | JANTZ DEREK Chief Scientific Officer | Sale | −7,048 | $11.68 | $82K | 3,877,204 |
| 2021-01-27 | JANTZ DEREK Chief Scientific Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −21,514 | 301,197 | ||
| 2021-01-26 | KANE MATTHEW R. President and CEO | Exercise or conversion | +21,515 | $0.04 | $861 | 1,863,708 |
| 2021-01-26 | KANE MATTHEW R. President and CEO | Sale | −9,697 | $13.37 | $130K | 1,854,011 |
| 2021-01-26 | KANE MATTHEW R. President and CEO | Exercise or conversion · Employee Stock Option (Right to Buy) | −21,515 | 258,168 | ||
| 2021-01-25 | KANE MATTHEW R. President and CEO | Exercise or conversion | +21,514 | $0.04 | $861 | 1,851,888 |
| 2021-01-25 | KANE MATTHEW R. President and CEO | Sale | −9,695 | $13.74 | $133K | 1,842,193 |
| 2021-01-25 | KANE MATTHEW R. President and CEO | Exercise or conversion · Employee Stock Option (Right to Buy) | −21,514 | 279,683 | ||
| 2021-01-22 | KANE MATTHEW R. President and CEO | Exercise or conversion | +21,514 | $0.04 | $861 | 1,840,592 |
| 2021-01-22 | KANE MATTHEW R. President and CEO | Sale | −10,218 | $13.53 | $138K | 1,830,374 |
| 2021-01-22 | KANE MATTHEW R. President and CEO | Exercise or conversion · Employee Stock Option (Right to Buy) | −21,514 | 301,197 | ||
| 2021-01-21 | THOMSON DAVID S. Chief Operating Officer | Sale | −10,000 | $16.49 | $165K | 109,243 |
| 2020-08-31 | Scimeca Dario General Counsel and Secretary | Grant or award | +3,156 | $4.79 | $15K | 5,228 |
| 2020-08-21 | KANE MATTHEW R. President and CEO | Grant or award · Employee Stock Option (Right to Buy) | +1,743 | 1,743 |
Page 24 of 28 · 549 trades